VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced that it completed a convertible note financing with an angel investor Dr. Tomy Kamada, through his investment firm TomyK Ltd., that supports technology startups which pioneer new markets and create new industries with their innovative technologies.
{iframe}http://vlptherapeutics.com/press-release-en/12680/{/iframe}